A randomized, double-blind, phase III study comparing biosimilar rituximab (RTXM83) plus CHOP chemotherapy versus a reference rituximab plus CHOP (R-CHOP) in patients with Diffuse Large B-Cell Lymphoma (DLBCL) given as first line

Trial Profile

A randomized, double-blind, phase III study comparing biosimilar rituximab (RTXM83) plus CHOP chemotherapy versus a reference rituximab plus CHOP (R-CHOP) in patients with Diffuse Large B-Cell Lymphoma (DLBCL) given as first line

Completed
Phase of Trial: Phase III

Latest Information Update: 22 Sep 2017

At a glance

  • Drugs Rituximab (Primary) ; Cyclophosphamide; Doxorubicin; Prednisolone; Prednisone; Vincristine
  • Indications Diffuse large B cell lymphoma
  • Focus Registrational; Therapeutic Use
  • Sponsors mAbxience
  • Most Recent Events

    • 19 Sep 2017 Status changed from active, no longer recruiting to completed.
    • 18 Sep 2017 Planned End Date changed from 1 Jul 2017 to 1 Jan 2018.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top